Leerink Swann Maintains an 'Outperform' on Vertex (VRTX); CF Conference Call Affirms Opportunity
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $399.50 -1.34%
Rating Summary:
31 Buy, 10 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
31 Buy, 10 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Leerink Swann maintains an 'Outperform' on Vertex (NASDAQ: VRTX) price target raised from $48 to $80.
Analyst, Howard Liang, said, "We hosted a conference call with a MEDACorp cystic fibrosis (CF) key opinion leader (KOL) to get an initial physician impression of the interim results from VRTX’s combination trial of KALYDECO/VX-809 in patients harboring homozygous delta F508 mutations (del F508) of the cystic fibrosis transmembrane conductance regulator (CFTR) announced yesterday. The KOL referred to the results as robust, exceeding his expectations. As the FEV1 findings were not as a result of abnormal behavior of the placebo group, he
anticipates the final results to generally hold up. Based on the data, we are increasing our assumed probability of success for the KALYDECO/VX-809 combination from 10% to 60% and increasing our PT."
For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.
Shares of Vertex closed at $58.12 yesterday.
Analyst, Howard Liang, said, "We hosted a conference call with a MEDACorp cystic fibrosis (CF) key opinion leader (KOL) to get an initial physician impression of the interim results from VRTX’s combination trial of KALYDECO/VX-809 in patients harboring homozygous delta F508 mutations (del F508) of the cystic fibrosis transmembrane conductance regulator (CFTR) announced yesterday. The KOL referred to the results as robust, exceeding his expectations. As the FEV1 findings were not as a result of abnormal behavior of the placebo group, he
anticipates the final results to generally hold up. Based on the data, we are increasing our assumed probability of success for the KALYDECO/VX-809 combination from 10% to 60% and increasing our PT."
For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.
Shares of Vertex closed at $58.12 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
- Adecco Group AG (ADEN:SW) (AHEXY) PT Lowered to CHF33 at Bernstein SocGen Group
- LG Innotek Co Ltd. (011070:KS) PT Raised to KRW300,000 at UBS
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
